Zydus gets USFDA nod for schizophrenia treatment drug
The company has got final approval from the USFDA to market the drug in the strengths of 25 mg, 50 mg, 100 mg and 200 mg, Zydus Cadila said in a BSE filing.
SEZ
-
Zydus Cadila gets tentative nod from USFDA to market 'Lenalidomide' cancer drug
Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood and bone marrow disorders (myelodysplastic syndromes-MDS).
-
Zydus Cadila gets tentative nod from USFDA to market cancer drug
-
Zydus Cadila gets USFDA tentative nod for epilepsy treatment drug
-
Zydus Cadila gets USFDA nod for low blood pressure drug
-
Three govt agencies launch probe in Serum Institute fire
-
Zydus Cadila gets tentative USFDA nod for generic drug
-
Zydus Cadila gets American health regulator's approval to market mineral supplement
-
IT, pharma SEZs beat slowdown blues
-
Lupin gets more time from govt to complete project in Indore SEZ
Advertisement
More in SEZ
Advertisement
Get updates on your preferred social platform
Follow us for the latest news, insider access to events and more.
